A Woman Dies of Postpartum Haemorrhage Every 12 Minutes. A Landmark Lancet Series Charts Why So Many Cases Are Still Being Missed — and What Must Change.

Postpartum haemorrhage (PPH) kills an estimated 43,000 women every year — one death every 12 minutes — and affects approximately 27 million women annually worldwide, according to a landmark three-paper Lancet Series published in June 2026. The series represents the most comprehensive reassessment of PPH epidemiology, diagnosis, and treatment in a generation.

Scale of the problem

PPH affects an estimated 17 million women following vaginal birth and 10 million following caesarean section each year. Pooled prevalence is 12.6% (95% CI 10.1–15.2%) for vaginal births and 30.9% (95% CrI 24.9–37.6%) for caesarean births. The global economic burden is estimated at $10.4 billion (95% CrI $9.8–13.2 billion) per year, comprising $3.6 billion in direct health-system costs and $6.8 billion in broader societal costs.

The diagnostic blind spot

One of the series’ most striking findings concerns how PPH is detected. A systematic review found that subjective visual estimation of blood loss — the method most commonly used at the bedside — has a pooled sensitivity of just 48% (95% CI 44–53%) at vaginal birth, meaning it misses more than half (52%) of PPH diagnoses. In response, the WHO has updated its clinical guidance. The new definition of PPH now encompasses: (1) objectively measured blood loss of ≥300 mL plus any abnormal haemodynamic sign (such as tachycardia or hypotension), or (2) blood loss of ≥500 mL or more. The lower threshold with a haemodynamic trigger is intended to prompt earlier intervention.

Treatment evidence

A Cochrane network meta-analysis (NMA) of 122 randomised controlled trials involving 121,931 women compared uterotonic agents for prevention of PPH. Combinations of oxytocin plus misoprostol, or oxytocin plus ergometrine, were the most effective prophylactic regimens. Among single agents, oxytocin and carbetocin were identified as most effective. Ergometrine alone and the oxytocin-plus-ergometrine combination are no longer recommended as routine first-line choices due to an increased risk of hypertension and associated adverse effects.

The three Lancet papers are: Coomarasamy et al., DOI: 10.1016/S0140-6736(26)00902-5; DOI: 10.1016/S0140-6736(26)00903-7; DOI: 10.1016/S0140-6736(26)01031-7. All are peer-reviewed.